Drugmakers are consistently searching for clinical trial participants and many pharma companies pay hospitals big bucks to test their medicines, sometimes at more than $10,000 per patient.
By operating as a single consortium, smaller regional hospitals are hoping to keep pace with larger academic medical centers, which tend to host a lot of active clinical trials thanks to their larger patient bases and renowned staff.
In April, Danville, Pa.-based Geisinger and five other local health systems formed a consortium to increase participation in drug trials, while a group of rural hospitals in North Dakota recently ramped up its partnerships in the hopes of expanding trial accessibility.
“As a group we’re stronger than just one,” James Brazeal, Geisinger chief administrative research officer, told Bloomberg. “We’re able to leverage that so we have more of an ability to participate, so that we can attract some of the trials that we couldn’t attract before.”
The new strategy is also beneficial for drugmakers, which say hosting clinical trials across several hospitals is cheaper and more efficient because they face fewer regulatory review boards, according to Bloomberg.
More articles on pharmacy:
Pfizer will likely hike drug prices come January
Novartis scraps 90 drug research programs
J&J loses patent fight over prostate cancer blockbuster
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.